IL23A and synovial sarcoma: Long-term efficacy of Ustekinumab, a human monoclonal antibody directed against the p40 protein subunit shared by IL-12 and IL-23, in a patient suffering from psoriasis and SS has been recorded on both the cutaneous and joint component (240).